Linvoseltamab-Gcpt 5 mg/2.5 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/2.5 mL
Reference Brands: Lynozyfic (USA/EU)
Category: Oncology Cancer Care
Linvoseltamab‑gcpt is a bispecific T‑cell engager antibody that binds to CD3 on T‑cells and BCMA on malignant plasma (myeloma) cells. This facilitates T‑cell activation and directs T cells to kill multiple myeloma cells. Lynozyfic is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, im‑modulatory agent and an anti‑CD38 antibody).
Linvoseltamab-Gcpt — third party manufacturing & bulk supply
Linvoseltamab-Gcpt 5 mg/2.5 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Linvoseltamab-Gcpt is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Linvoseltamab-Gcpt listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Linvoseltamab-Gcpt →Frequently Asked Questions
Linvoseltamab‑gcpt is used to treat adults with relapsed or refractory multiple myeloma, particularly those who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody.
It is a bispecific T‑cell engaging antibody produced in cell culture, designed to bind CD3 on T‑cells and B‑cell maturation antigen (BCMA) on multiple myeloma cells, directing T‑cells to kill the cancer cells.
The trade name is Lynozyfic.
It is manufactured by Regeneron Pharmaceuticals, Inc.
The generic name is linvoseltamab‑gcpt.
The brand name is Lynozyfic.
It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cell culture and formulated as a sterile intravenous drug.
Related Products
Denileukin Diftitox
Strength:
300 mcg
Form: Injection
Reference Brands: Lymphir (USA/EU), Ontak (USA/EU)
View Details
Lutetium Lu 177 Dotatate
Strength:
7.4 GBq/ vial
Form: Injection
Reference Brands: Lutathera (USA, EU)
View Details
Mosunetuzumab-Axgb
Strength:
1 mg/mL
Form: Injection
Reference Brands: Lunsumio (USA/EU)
View Details
Trametinib
Strength:
0.5 mg, 1 mg, 2 mg
Form: Tablets
Reference Brands: Mekinist (USA/EU)
View Details
Ifosfamide
Strength:
1 g/vial,2 g/vial, 3 g/vial
Form: Injection
Reference Brands: Ifex® (US), Holoxan® (EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
